Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax

Jiao,Feng; Hu,Hai; Yuan,Cuncun; Jin,Ziliang; Guo,Zhen; Wang,Liwei; Wang,Lei

doi:10.3892/ijo.2014.2568

Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax

Authors:
- Feng Jiao
- Hai Hu
- Cuncun Yuan
- Ziliang Jin
- Zhen Guo
- Liwei Wang
- Lei Wang
View Affiliations

Affiliations: Department of Oncology, First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201620, P.R. China, Department of Pathology, First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201620, P.R. China
Published online on: July 29, 2014 https://doi.org/10.3892/ijo.2014.2568
Pages: 1523-1530

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is one of the most aggressive solid malignancies with a dismal survival rate. Recent studies have shown that high expression levels of histone deacetylase 3 (HDAC3) correlate with malignant phenotype. However, the expression patterns and biological role of HDAC3 in pancreatic cancer remain unclear. In this study, our data showed that a higher level of HDAC3 protein expression was found in pancreatic cancer as compared to paired paracancerous tissues. Consistently, higher expression level of HDAC3 was found in all of the eight pancreatic cancer cell lines relative to human pancreatic ductal epithelial cells (HPDE). In addition, further function analysis revealed that HDAC3 can function as oncogenic protein, which could promote pancreatic cancer cell proliferation, migration and invasion, and may increase drug resistance. Moreover, the functional involvement of HDAC3 was partially correlated with post-induction repression of P53, P27 and Bax gene transcription, acting via H3K9 deacetylation. Taken together, our data suggest that HDAC3 participates in the pathogenesis and progression of pancreatic cancer through histone modification, which might be a pivotal epigenetic target against this devastating disease.

View Figures

View References

1	Ducreux M, Boige V, Goere D, Deutsch E, Ezra P, Elias D and Malka D: The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure. Best Pract Res Clin Gastroenterol. 21:997–1014. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ghaneh P, Costello E and Neoptolemos JP: Biology and management of pancreatic cancer. Postgrad Med J. 84:478–497. 2008. View Article : Google Scholar
3	Chueh AC, Togel L, Mariadason J and Tse JW: Mechanisms of HDAC inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal. March 27–2014.[Epub ahead of print].
4	West AC and Johnstone RW: New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 124:30–39. 2014. View Article : Google Scholar : PubMed/NCBI
5	Barneda-Zahonero B and Parra M: Histone deacetylases and cancer. Mol Oncol. 6:579–589. 2012. View Article : Google Scholar
6	Huang X, Ji G, Wu Y, Wan B and Yu L: LAMA4, highly expressed in human hepatocellular carcinoma from Chinese patients, is a novel marker of tumor invasion and metastasis. J Cancer Res Clin Oncol. 134:705–714. 2008. View Article : Google Scholar : PubMed/NCBI
7	Xue Y, Ren H, Xiao W, Chu Z, Lee JJ and Mao L: Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. Int J Oncol. 41:1798–1808. 2012.PubMed/NCBI
8	Giovannetti E, Del TM, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del CM, Iannopollo M, Bevilacqua G, Mosca F and Danesi R: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66:3928–3935. 2006. View Article : Google Scholar
9	Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L and Depinho RA: Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA. 103:5947–5952. 2006. View Article : Google Scholar : PubMed/NCBI
10	Ansari D, Rosendahl A, Elebro J and Andersson R: Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 98:1041–1055. 2011. View Article : Google Scholar : PubMed/NCBI
11	Hamada S, Masamune A, Miura S, Satoh K and Shimosegawa T: MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal. 26:179–185. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chen Z, Chen LY, Dai HY, Wang P, Gao S and Wang K: miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem. 113:3229–3235. 2012. View Article : Google Scholar : PubMed/NCBI
13	Genin P, Lin R, Hiscott J and Civas A: Recruitment of histone deacetylase 3 to the interferon-A gene promoters attenuates interferon expression. PLoS One. 7:e383362012. View Article : Google Scholar : PubMed/NCBI
14	Karagianni P and Wong J: HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene. 26:5439–5449. 2007. View Article : Google Scholar : PubMed/NCBI
15	Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, Bell GW, Walker K, Rolfe PA, Herbolsheimer E, Zeitlinger J, Lewitter F, Gifford DK and Young RA: Genome-wide map of nucleosome acetylation and methylation in yeast. Cell. 122:517–527. 2005. View Article : Google Scholar : PubMed/NCBI
16	Guenther MG, Levine SS, Boyer LA, Jaenisch R and Young RA: A chromatin landmark and transcription initiation at most promoters in human cells. Cell. 130:77–88. 2007. View Article : Google Scholar : PubMed/NCBI
17	Liu C, Liu L, Shan J, Shen J, Xu Y, Zhang Q, Yang Z, Wu L, Xia F, Bie P, Cui Y, Zhang X, Bian X and Qian C: Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. Cancer Lett. 339:60–69. 2013. View Article : Google Scholar : PubMed/NCBI
18	Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Motoyama S and Ogawa J: Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol. 31:533–539. 2010. View Article : Google Scholar : PubMed/NCBI
19	Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M and Kristiansen G: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 98:604–610. 2008. View Article : Google Scholar : PubMed/NCBI
20	Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW, Wu J and Zheng SS: Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One. 5:e144602010. View Article : Google Scholar : PubMed/NCBI
21	Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH and Davidsen SK: Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun. 310:529–536. 2003. View Article : Google Scholar : PubMed/NCBI
22	Zhu J, Wan H, Xue C, Jiang T, Qian C and Zhang Y: Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration. Brain Res. 1520:15–22. 2013. View Article : Google Scholar : PubMed/NCBI
23	Campos B, Bermejo JL, Han L, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, Unterberg A and Herold-Mende C: Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci. 102:387–392. 2011. View Article : Google Scholar : PubMed/NCBI
24	Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW and Giardina C: HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog. 47:137–147. 2008. View Article : Google Scholar : PubMed/NCBI
25	Sonnemann J, Marx C, Becker S, Wittig S, Palani CD, Kramer OH and Beck JF: p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br J Cancer. 110:656–667. 2014. View Article : Google Scholar : PubMed/NCBI
26	Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R, Grizzle WE, Rao VN, Bhat GK and Reddy ES: Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol. 39:111–119. 2011.
27	Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY and Nam SW: HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem. 113:2167–2177. 2012. View Article : Google Scholar : PubMed/NCBI
28	Nimmanapalli R, Fuino L, Stobaugh C, Richon V and Bhalla K: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 101:3236–3239. 2003. View Article : Google Scholar
29	Huang L and Pardee AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med. 6:849–866. 2000.PubMed/NCBI
30	Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET and Yu Q: Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA. 102:16090–16095. 2005. View Article : Google Scholar : PubMed/NCBI
31	Xu W, Ngo L, Perez G, Dokmanovic M and Marks PA: Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA. 103:15540–15545. 2006. View Article : Google Scholar : PubMed/NCBI
32	Reichert N, Choukrallah MA and Matthias P: Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci. 69:2173–2187. 2012. View Article : Google Scholar : PubMed/NCBI